Last updated on April 2018

PET Imaging CCR2 in Lung Inflammation


Brief description of study

The primary objective of this study is to determine the safety of the novel probe 64Cu-DOTA-ECL1i for PET imaging of CCR2 expression.

Detailed Study Description

This is a single site, pilot Phase 0/1 clinical trial to establish initial estimates of the human radiation dosimetry of 64Cu-DOTA-ECL1i. Healthy volunteers and participants who currently smoke cigarettes but do not have known pulmonary disease will be recruited. Twelve participants (N=6 healthy, N=6 current smokers) will undergo whole-body PET/CT and PET/MR imaging at multiple time points after 64Cu-DOTA-ECL1i injection to determine the human dosimetry for this tracer.

Clinical Study Identifier: NCT03492762

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.